Long-Term Debt: Synthetic Biologics (TOVX)

Brandmark of Theriva Corp (TOVX)

Theriva Biologics, Inc. (TOVX) focuses on developing immune-based drugs, outsourcing the design of viral vectors and protocols to external contractors. This chart illustrates the asset's market value on the GURU.Markets platform at 0.00. The company is implementing automated laboratories to scale drug production with a small workforce, while close collaboration with CROs during oncolytic virus testing mitigates operational risks.

TOVX (Synthetic Biologics) Company Long-Term Debt history from 04/28/2023 to 11/01/2026

Synthetic Biologics - analytical breakdowns and key metrics (TOVX)

- current quotes and average value forecast:
Stock Quotes therivabio.com|TOVX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Theriva Biologics|TOVX - Total Company Value
- book capitalization data:
Net Assets per Single Share Theriva Biologics|TOVX - Company Book Value|Market-to-Book Ratio therivabio.com|TOVX - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Theriva Biologics, Inc.|TOVX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Theriva Corp|TOVX - Company Total Debt|Debt to Net Assets Ratio Theriva Biologics|TOVX - Company Long-Term Debts|Short-Term Debt Volume Theriva Biologics|Quick Liquidity Indicator therivabio.com
- net income and valuation multiples indicators:
TOVX - Company Net Income
Fundamental company valuation:therivabio.com
Core merchandise of Theriva Biologics

Theriva Biologics, Inc. (TOVX) outsourcing of production to third-party cGMP facilities is directly reflected in the organization's long-term debt structure. This metric accumulates obligations with maturities exceeding one year. Daily data recalculations eliminate the time gap between quarterly reports. Monitoring the trend allows for an assessment of the balance between leverage and default risk. This confirms the effectiveness of the model for minimizing capital expenditures in physical assets.

Who Theriva Biologics, Inc. competes with

IBRX - Company Long-Term Liabilities|IMCR - Company Long-Term Debt|Long-Term Debt Janux Therapeutics Inc|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt Tango Therapeutics|Long-Term Debt iovance.com IOVA|Company Long-Term Debts IMTX|Xencor Inc (XNCR) - Long-Term Indebtedness|Compass Bio - Company Long-Term Liabilities|Replimune Inc. (REPL) - Long-Term Debt|LYEL: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Long-Term Debts|CGEN - Long-Term Debt Volume|Company Long-Term Debt IO Biotech Corp|Company Long-Term Liabilities Sutro Biopharma, Inc (STRO)|Company Long-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Long-Term Liabilities werewolftx.com HOWL|Immix Biopharma - Company Long-Term Liabilities|Company Long-Term Debts alxoncology.com ALXO|CUE - Company Long-Term Debt|PDSB (PDS Biotechnology) - Company Long-Term Indebtedness|sonnetbio.com (SONN) - Company Long-Term Debt|Long-Term Debt MAIABiotech.com (MAIA)|Company Long-Term Liabilities LIMN|LVTX - Long-Term Indebtedness|Company Long-Term Liabilities NXTC (NextCure Corp)|Amount of Long-Term Liabilities LPTX|Company Long-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Long-Term Loans and Borrowings SNSE|Gritstone Bio - Company Long-Term Debts|Long-Term Debt Kineta Inc|NexImmune Corp (NEXI) - Company Long-Term Debt|Turnstone Biologics Corp. - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts harpoontx.com